Paper29517954
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Brahmer JR and 2 others. J Oncol Pract, 2018. Cited by 351 papers, by iCite.
Cite this record
ConductScience Library. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Papers, record 29517954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29517954
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Molecular Targeted Therapy | Major topic |
| Neoplasms | Major topic |
| Biomarkers, Tumor | |
| Disease Management | |
| Humans |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | Background | ClinicalTrials.gov | |
| NCT05867004 | Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 30020818 | Reply to D.L. Kimpel et al. | https://conductscience.org/library/papers/30020818 | PubMed |
| Comment in | 30020819 | Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy. | https://conductscience.org/library/papers/30020819 | PubMed |
Cited by257
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 351 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958364 | Immune checkpoints: cross-disease insights and clinical dilemmas. | Biomark Res | 2026 | https://conductscience.org/library/papers/42958364 | PubMed |
| 42831226 | Differentiating Persistent Sepsis From Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis and Concurrent Immune-Mediated Nephritis: A Diagnostic and Therapeutic Challenge. | Cureus | 2026 | https://conductscience.org/library/papers/42831226 | PubMed |
| 42820064 | The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact. | J Immunother Precis Oncol | 2026 | https://conductscience.org/library/papers/42820064 | PubMed |
| 42763605 | Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes. | Cureus | 2026 | https://conductscience.org/library/papers/42763605 | PubMed |
| 42633201 | Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab. | Cureus | 2026 | https://conductscience.org/library/papers/42633201 | PubMed |
| 42534193 | Aseptic Meningitis With Multiple Cranial Nerve Symptoms Induced by Atezolizumab for Lung Adenocarcinoma: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42534193 | PubMed |
| 42524550 | The Real-World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42524550 | PubMed |
| 42491088 | Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy. | Front Public Health | 2026 | https://conductscience.org/library/papers/42491088 | PubMed |
| 42483135 | Cytomegalovirus (CMV) Co-infection in Treatment-Refractory Immune Checkpoint Inhibitor-Associated Colitis: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42483135 | PubMed |
| 42460315 | Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42460315 | PubMed |
| 42426360 | Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42426360 | PubMed |
| 42360103 | Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42360103 | PubMed |
| 42292465 | Severe immune checkpoint inhibitor-induced 3M syndrome: a case report. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292465 | PubMed |
| 42189338 | Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42189338 | PubMed |
| 42181373 | Myositis-Myasthenia Overlap Syndrome After Immune Checkpoint Inhibitor Treatment: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42181373 | PubMed |
| 42134550 | Prospective serial cardiovascular magnetic resonance imaging of immune checkpoint inhibitor myocarditis correlates with cardiovascular outcomes. | J Cardiovasc Magn Reson | 2026 | https://conductscience.org/library/papers/42134550 | PubMed |
| 42122148 | PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122148 | PubMed |
| 42099345 | When Immunotherapy Hits the Joints: A Case of Late-Onset Polyarthritis Induced by an Immune Checkpoint Blockade and Literature Review. | Cureus | 2026 | https://conductscience.org/library/papers/42099345 | PubMed |
| 42037888 | Gastrointestinal Toxicities of Targeted Cancer Therapies: A Narrative Review. | Cureus | 2026 | https://conductscience.org/library/papers/42037888 | PubMed |
| 41959988 | A Persistent Pneumonia or an Uncommon Condition: A Case of Immunotherapy-Induced Pneumonitis. | Cureus | 2026 | https://conductscience.org/library/papers/41959988 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29517954
GET https://conductscience.org/api/papers/v1/29517954/cited_by?page=2